Oral orforglipron helped adults maintain clinically meaningful weight loss after prior injectable tirzepatide or semaglutide therapy. The phase 3b ATTAIN-MAINTAIN trial suggests switching to once-daily oral therapy may help reduce weight regain when injectable treatment is discontinued.